Literature DB >> 18493224

European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe: executive summary.

Timo Vesikari1, Pierre Van Damme, Carlo Giaquinto, Jim Gray, Jacek Mrukowicz, Ron Dagan, Alfredo Guarino, Hania Szajewska, Vytautas Usonis.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18493224     DOI： 10.1097/MPG.0b013e31816e213a

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN： 0277-2116            Impact factor:   2.839


× No keyword cloud information.
  15 in total

Review 1.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

Review 2.  Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

3.  A 4-year study on clinical characteristics of children hospitalized with rotavirus gastroenteritis.

Authors:  Stefanie Wildi-Runge; Simone Allemann; Urs B Schaad; Ulrich Heininger
Journal:  Eur J Pediatr       Date:  2009-02-11       Impact factor: 3.183

Review 4.  Acute infectious diarrhea in children.

Authors:  Sibylle Koletzko; Stephanie Osterrieder
Journal:  Dtsch Arztebl Int       Date:  2009-08-14       Impact factor: 5.594

5.  The impact of childhood acute rotavirus gastroenteritis on the parents' quality of life: prospective observational study in European primary care medical practices.

Authors:  Javier Diez Domingo; Marian Patrzalek; Luigi Cantarutti; Benoit Arnould; Juliette Meunier; Montse Soriano-Gabarro; Nadia Meyer; Jean-Yves Pirçon; Katsiaryna Holl
Journal:  BMC Pediatr       Date:  2012-05-31       Impact factor: 2.125

6.  Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in developed countries.

Authors:  Greg L Plosker
Journal:  Drugs R D       Date:  2012-12-01

7.  Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination.

Authors:  Patricia Bruijning-Verhagen; Marie-Josée J Mangen; Mariet Felderhof; Nico G Hartwig; Marlies van Houten; Léon Winkel; Wouter J de Waal; Marc J M Bonten
Journal:  BMC Med       Date:  2013-04-26       Impact factor: 8.775

8.  Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model.

Authors:  Mark H Rozenbaum; Marie-Josee J Mangen; Carlo Giaquinto; Jan C Wilschut; Eelko Hak; Maarten J Postma
Journal:  BMC Public Health       Date:  2011-06-10       Impact factor: 3.295

Review 9.  Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.

Authors:  Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2011-05       Impact factor: 4.558

Review 10.  Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries.

Authors:  Greg L Plosker
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.930
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.